SVB Wealth LLC Invests $928,000 in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

SVB Wealth LLC bought a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 8,786 shares of the medical equipment provider’s stock, valued at approximately $928,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Equity Investment Corp purchased a new position in shares of Zimmer Biomet during the third quarter valued at about $70,104,000. Hotchkis & Wiley Capital Management LLC grew its holdings in Zimmer Biomet by 49.1% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock valued at $189,161,000 after buying an additional 577,320 shares in the last quarter. Thompson Siegel & Walmsley LLC bought a new stake in Zimmer Biomet in the 3rd quarter worth approximately $41,588,000. Van ECK Associates Corp raised its holdings in shares of Zimmer Biomet by 5.9% during the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider’s stock worth $417,814,000 after acquiring an additional 218,688 shares in the last quarter. Finally, FMR LLC boosted its position in shares of Zimmer Biomet by 27.6% during the 3rd quarter. FMR LLC now owns 750,336 shares of the medical equipment provider’s stock valued at $80,999,000 after acquiring an additional 162,384 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Price Performance

Shares of ZBH stock opened at $105.26 on Tuesday. The company has a market capitalization of $20.95 billion, a P/E ratio of 23.65, a P/E/G ratio of 1.95 and a beta of 1.02. The company’s 50-day simple moving average is $105.69 and its two-hundred day simple moving average is $107.32. Zimmer Biomet Holdings, Inc. has a one year low of $97.69 and a one year high of $133.90. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the company earned $2.20 EPS. As a group, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a $0.24 dividend. The ex-dividend date is Monday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 0.91%. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Analysts Set New Price Targets

A number of research firms recently issued reports on ZBH. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their price target for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. Raymond James lowered their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Truist Financial reissued a “hold” rating and set a $113.00 price objective (down from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. JMP Securities restated a “market outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a report on Friday, February 7th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and an average target price of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.